BioCardia (BCDA) Q4 2024 earnings summary

Executive summary

• Announced primary outcome data from the CardiAMP Heart Failure Trial, showing strong signals of benefit in cardiac death equivalents and major adverse cardiovascular events, though the primary endpoint was not met due to the six-minute walk distance tier.

• Reported 2024 financial results and business highlights, including progress in clinical trials for CardiAMP and CardiALLO cell therapies.

• Quality of life improvements and reduced arrhythmias were observed, with statistical significance in patients with elevated NT-proBNP.

• Regulatory discussions are ongoing with the FDA and Japan's PMDA, with potential for conditional or full approval in Japan.

• Launched commercial Morph DNA steerable introducer devices for clinical and commercial use.

Financial highlights

• Total expenses decreased 35% year-over-year to $8.1 million in 2024, primarily due to lower R&D costs after trial completion.

• Net loss narrowed to $7.9 million from $11.6 million in 2023, reflecting lower R&D and SG&A expenses.

• R&D expenses fell 43% to $4.4 million; SG&A expenses decreased 16% to $3.7 million.

• Cash and cash equivalents at year-end were $2.4 million, up from $1.1 million at the end of 2023.

• Revenues were $58,000 in 2024, down from $477,000 in 2023, mainly due to completion of performance obligations.

Outlook and guidance

• R&D expenses expected to rise modestly in 2025 as development continues in the US and Japan.

• Anticipates presenting CardiAMP HF data at ACC 2025, with potential to support product registration.

• Plans to submit clinical data to FDA and Japan's PMDA and accelerate enrollment in CardiAMP HF II Trial.

• SG&A expenses projected to remain stable.

• Upcoming milestones include Data Safety Monitoring Board review for CardiALLO and publication of BCDA-02 cohort data.